Amsterdam’s myTomorrows raises $29M to speed up global access to experimental medicines
Scaling a global treatment-access platform
Amsterdam’s life sciences ecosystem has added another milestone as myTomorrows, one of the city’s most internationally recognised health-tech scaleups, secured $29 million to expand its global platform for accessing experimental treatments. The investment, led by Avego, marks a significant boost for the Amsterdam Metropolitan Area’s growing reputation as a hub for patient-centred medical innovation.
myTomorrows was founded in 2012 to address a gap in global healthcare: patients facing serious illnesses often struggle to find or qualify for clinical trials or early-access programmes, even when promising therapies exist. The fresh funding will accelerate global expansion, strengthen the company’s collaborations with the pharmaceutical industry, and enhance the real-world data capabilities that support future approvals and improve patient outcomes.
The platform searches across numerous international clinical trial registries and integrates securely with electronic health records, helping physicians identify suitable programmes quickly and safely. Alongside its digital infrastructure, the company provides hands-on support to help patients navigate paperwork, referrals, and regulatory hurdles, areas that often slow early access to emerging therapies.
Amsterdam’s role in accelerating access to experimental treatments
For Amsterdam, a city steadily shaping Europe’s life sciences landscape, the news shows the region’s strength as a hub for health-tech companies with global ambitions. With fresh investment and a growing network of BioPharma partners, myTomorrows is set to improve access to experimental treatments for patients worldwide.
They’re part of a wider local community pushing the field forward: Kite Pharma operates a major cell therapy manufacturing site in the city, and Neogene Therapeutics develops engineered T-cell therapies from its Amsterdam office, further evidence of a cluster focused on next-generation treatments.